Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DME Competitive Bidding: 32% Cost-Cutting Expected From Revived Program

This article was originally published in The Gray Sheet

Executive Summary

CMS plans to cut reimbursement an average 32% next year for certain durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) sold in nine markets, the agency announced July 1

You may also be interested in...

CMS Considers Inherent Reasonableness Rule To Lower Pay For Diabetes Test Supplies

The use of a relatively obscure CMS fee-adjustment authority rather than competitive bidding to lower Medicare payment for diabetes testing supplies in the retail setting could be precedent setting.

Medicare Fee-For-Service Program Still A Key Focus At CMS

Center for Medicare Director Jonathan Blum spoke during the Medicare-Medicaid Payment Incentives and Penalties Summit May 30 in Washington, D.C.

Reimbursement In Brief

Latest news from the Medicare agency and other payers.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts